RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Actually, now that I check my records,let me correct two things I said. Takeda and Pfizer ran Phase Ib studies--the former in adult ADHD, the latter in schizophrenia, including a ketamine model (they ran a number of Phase I and Ib trials). Takeda terminated their Phase Ib, so something must have come up re: safety (seizure?).

Pfizer ran a number of trials, so they must have been OK with human safety, the most recent one was a multiple ascending dose study in schizophrenia.Someone had told me that this program was being ended, but it is still listed on their pipeline, so it apparently has survived thus far, including a few Phase Ib trials.

Servier ran a full Phase II in patients with both Alzheimer's and depression. They havent announced the results--but it failed on efficacy. So all three of the compounds passed the animal testing/histopathology hurdle. Two ended, due to two different issues.

But Pfizer's sz program has NOT ended yet, at least not officially. Nor have they announced anything about going further into PhII, so I don't know if what I heard was wrong, or prematurely correct. If they were to go ahead into Phase II for sz, that would help with the task of resurrecting Ampakine-type drugs in the eyes of potential partners.

NP